{
    "2020-05-31": [
        [
            {
                "time": "2019-12-15",
                "original_text": "Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT速 (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma",
                "features": {
                    "keywords": [
                        "Innovent Biologics",
                        "Lilly",
                        "TYVYT速",
                        "Sintilimab Injection",
                        "Long-Term Follow-Up Results",
                        "Relapsed/Refractory Classic Hodgkin's Lymphoma"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2020-03-20",
                "original_text": "Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT速 (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma",
                "features": {
                    "keywords": [
                        "Innovent Biologics",
                        "Lilly",
                        "TYVYT速",
                        "Sintilimab Injection",
                        "Pivotal Clinical Study Results",
                        "Second-Line Treatment",
                        "Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-07-10",
                "original_text": "Bristol-Myers Deserves Better Than a Single-Digit Multiple",
                "features": {
                    "keywords": [
                        "Bristol-Myers",
                        "Single-Digit Multiple"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}